Utility of nintedanib for severe idiopathic pulmonary fibrosis: a single-center retrospective study [Corrigendum]

Abstract

Abe M, Tsushima K, Sakayori M, et al. Drug Des Devel Ther. 2018;12:3369–3375. On page 3372, last paragraph of “Results” section should read from “In Severe Group, patients who were able to continue nintedanib for more than 3 months (n = 4) exhibited significantly better prognosis compared to those who could not (n = 13) (P = 0.007) (Figure 6).” to “In Severe Group, patients who were able to continue nintedanib for more than 3 months (n = 13) exhibited significantly better prognosis compared to those who could not (n = 4) (P = 0.007) (Figure 6).”